Microglia, Alzheimer's disease, and complement

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Crehan, Helen ^a   Hardy, John ^a   Pocock, Jennifer ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT; CYTOKINE; LECTIN;

ALZHEIMER DISEASE; APOPTOSIS; COMPLEMENT ALTERNATIVE PATHWAY; HUMAN; MICROGLIA; MODULATION; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84866246671     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/983640     Document Type: Review

References (125)

1. Morgan B. P., Gasque P., Expression of complement in the brain: role in health and disease. Immunology Today 1996 17 10 461 466 2-s2.0-0030271257 10.1016/0167-5699(96)20028-F
2. Yasojima K., Schwab C., McGeer E. G., McGeer P. L., Up-regulated production and activation of the complement system in Alzheimer's disease brain. American Journal of Pathology 1999 154 3 927 936 2-s2.0-0033061855
3. Dunkelberger J. R., Song W. C., Complement and its role in innate and adaptive immune responses. Cell Research 2010 20 1 34 50 2-s2.0-73849090193 10.1038/cr.2009.139
4. Sarma J. V., Ward P. A., The complement system. Cell and Tissue Research 2011 343 1 227 235 2-s2.0-79151475628 10.1007/s00441-010-1034-0
5. Murphy K., Travers P., Walport M., Janeway's Immuno Biology 2008 7th New York, NY, USA Garland Science, Taylor & Francis group, LLC
6. Sorensen R., Thiel S., Jensenius J. C., Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Seminars in Immunopathology 2005 27 3 299 319 2-s2.0-27844451895 10.1007/s00281-005-0006-z
7. Qu H., Ricklin D., Lambris J. D., Recent developments in low molecular weight complement inhibitors. Molecular Immunology 2009 47 2-3 185 195 2-s2.0-70450224874 10.1016/j.molimm.2009.08.032
8. Liu D., Niu Z. X., The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacology and Immunotoxicology 2009 31 4 524 535 2-s2.0-70449120924 10.3109/08923970902845768
9. 2+ on the lytic process. Journal of Immunology 1987 138 5 1530 1536 2-s2.0-0023106588
10. Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J., Human protectin (CD59), an 18,00020,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990 71 1 1 9 2-s2.0-0025179976
11. Frank M. M., Fries L. F., The role of complement in inflammation and phagocytosis. Immunology Today 1991 12 9 322 326 2-s2.0-0025781819
12. McGreal E., Gasque P., Structure-function studies of the receptors for complement C1q. Biochemical Society Transactions 2002 30 6 1010 1014 2-s2.0-0036864199 10.1042/BST0301010
13. Nelson R. A. Jr., The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 1953 118 3077 733 737
14. Holers V. M., Chaplin D. D., Leykam J. F., Human complement C3b/C4b receptor (CRI) mRNA polymorphism that correlates with the CRI allelic molecular weight polymorphism. Proceedings of the National Academy of Sciences of the United States of America 1987 84 8 2459 2463 2-s2.0-0023259335
15. Krych-Goldberg M., Atkinson J. P., Structure-function relationships of complement receptor type 1. Immunological Reviews 2001 180 112 122 2-s2.0-0035018479 10.1034/j.1600-065X.2001.1800110.x
16. Fearon D. T., Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. Journal of Experimental Medicine 1980 152 1 20 30 2-s2.0-0018875296
17. Appary M. D., Kazatchkine M. D., Levi-Strauss M., Hinglais N., Bariety J., Expression of CR1 (CD35) mRNA in podocytes from adult and fetal human kidneys. Kidney International 1990 38 2 289 293 2-s2.0-0024997959
18. Crehan H., Holton P., Wray S., Pocock J., Guerreiro R., Hardy J., Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology 2012 217 2 244 250 2-s2.0-84855260369 10.1016/j.imbio.2011.07.017
19. Schifferli J. A., Ng Y. C., Estreicher J., Walport M. J., The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. Journal of Immunology 1988 140 3 899 904 2-s2.0-0023846387
20. Ertekin-Taner N., Genetics of Alzheimer's disease: a centennial review. Neurologic Clinics 2007 25 3 611 667 2-s2.0-34447316702 10.1016/j.ncl.2007.03. 009
21. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M. L., Pahwa J. S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A. R., Lovestone S., Powell J., Proitsi P., Lupton M. K., Brayne C., Rubinsztein D. C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K. S., Passmore P. A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A. D., Love S., Kehoe P. G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schürmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Hüll M., Rujescu D., Goate A. M., Kauwe J. S. K., Cruchaga C., Nowotny P., Morris J. C., Mayo K., Sleegers K., Bettens K., Engelborghs S., de Deyn P. P., van Broeckhoven C., Livingston G., Bass N. J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C. E., Tsolaki M., Singleton A. B., Guerreiro R., Mühleisen T. W., Nöthen M. M., Moebus S., Jöckel K. H., Klopp N., Wichmann H. E., Carrasquillo M. M., Pankratz V. S., Younkin S. G., Holmans P. A., O'Donovan M., Owen M. J., Williams J., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics 2009 41 10 1088 1093 2-s2.0-70349558631 10.1038/ng.440
22. Lambert J. C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M. J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fiévet N., Barberger-Gateau P., Engelborghs S., de Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M. M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Boss P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanché H., Dartigues J. F., Tzourio C., Gut I., van Broeckhoven C., Alpérovitch A., Lathrop M., Amouyel P., Arosio B., Coto E., Zompo M. D., Deramecourt V., Epelbaum J., Forti P., Brice A., Ferri R., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Ravaglia G., Sahel J., Valdivieso F., Vepsäläinen S., Pilotto A., Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics 2009 41 10 1094 1099 2-s2.0-78549264026 10.1038/ng.439
23. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J. C., Carrasquillo M. M., Abraham R., Hamshere M. L., Pahwa J. S., Moskvina V., Dowzell K., Jones N., Stretton A., Thomas C., Richards A., Ivanov D., Widdowson C., Chapman J., Lovestone S., Powell J., Proitsi P., Lupton M. K., Brayne C., Rubinsztein D. C., Gill M., Lawlor B., Lynch A., Brown K. S., Passmore P. A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A. D., Beaumont H., Warden D., Wilcock G., Love S., Kehoe P. G., Hooper N. M., Vardy E. R. L. C., Hardy J., Mead S., Fox N. C., Rossor M., Collinge J., Maier W., Jessen F., Rüther E., Schürmann B., Heun R., Kölsch H., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Gallacher J., Hüll M., Rujescu D., Giegling I., Goate A. M., Kauwe J. S. K., Cruchaga C., Nowotny P., Morris J. C., Mayo K., Sleegers K., Bettens K., Engelborghs S., de Deyn P. P., van Broeckhoven C., Livingston G., Bass N. J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C. E., Tsolaki M., Singleton A. B., Guerreiro R., Mühleisen T. W., Nöthen M. M., Moebus S., Jöckel K. H., Klopp N., Wichmann H. E., Pankratz V. S., Sando S. B., Aasly J. O., Barcikowska M., Wszolek Z. K., Dickson D. W., Graff-Radford N. R., Petersen R. C., van Duijn C. M., Breteler M. M. B., Ikram M. A., Destefano A. L., Fitzpatrick A. L., Lopez O., Launer L. J., Seshadri S., Berr C., Campion D., Epelbaum J., Dartigues J. F., Tzourio C., Alpérovitch A., Lathrop M., Feulner T. M., Friedrich P., Riehle C., Krawczak M., Schreiber S., Mayhaus M., Nicolhaus S., Wagenpfeil S., Steinberg S., Stefansson H., Stefansson K., SnÆdal J., Björnsson S., Jonsson P. V., Chouraki V., Genier-Boley B., Hiltunen M., Soininen H., Combarros O., Zelenika D., Delepine M., Bullido M. J., Pasquier F., Mateo I., Frank-Garcia A., Porcellini E., Hanon O., Coto E., Alvarez V., Bosco P., Siciliano G., Mancuso M., Panza F., Solfrizzi V., Nacmias B., Sorbi S., Bossù P., Piccardi P., Arosio B., Annoni G., Seripa D., Pilotto A., Scarpini E., Galimberti D., Brice A., Hannequin D., Licastro F., Jones L., Holmans P. A., Jonsson T., Riemenschneider M., Morgan K., Younkin S. G., Owen M. J., O'Donovan M., Amouyel P., Williams J., Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics 2011 43 5 429 436 2-s2.0-79955484414 10.1038/ng.803
24. Naj A. C., Jun G., Beecham G. W., Wang L. S., Vardarajan B. N., Buros J., Gallins P. J., Buxbaum J. D., Jarvik G. P., Crane P. K., Larson E. B., Bird T. D., Boeve B. F., Graff-Radford N. R., de Jager P. L., Evans D., Schneider J. A., Carrasquillo M. M., Ertekin-Taner N., Younkin S. G., Cruchaga C., Kauwe J. S. K., Nowotny P., Kramer P., Hardy J., Huentelman M. J., Myers A. J., Barmada M. M., Demirci F. Y., Baldwin C. T., Green R. C., Rogaeva E., George-Hyslop P. S., Arnold S. E., Barber R., Beach T., Bigio E. H., Bowen J. D., Boxer A., Burke J. R., Cairns N. J., Carlson C. S., Carney R. M., Carroll S. L., Chui H. C., Clark D. G., Corneveaux J., Cotman C. W., Cummings J. L., Decarli C., Dekosky S. T., Diaz-Arrastia R., Dick M., Dickson D. W., Ellis W. G., Faber K. M., Fallon K. B., Farlow M. R., Ferris S., Frosch M. P., Galasko D. R., Ganguli M., Gearing M., Geschwind D. H., Ghetti B., Gilbert J. R., Gilman S., Giordani B., Glass J. D., Growdon J. H., Hamilton R. L., Harrell L. E., Head E., Honig L. S., Hulette C. M., Hyman B. T., Jicha G. A., Jin L. W., Johnson N., Karlawish J., Karydas A., Kaye J. A., Kim R., Koo E. H., Kowall N. W., Lah J. J., Levey A. I., Lieberman A. P., Lopez O. L., MacK W. J., Marson D. C., Martiniuk F., Mash D. C., Masliah E., McCormick W. C., McCurry S. M., McDavid A. N., McKee A. C., Mesulam M., Miller B. L., Miller C. A., Miller J. W., Parisi J. E., Perl D. P., Peskind E., Petersen R. C., Poon W. W., Quinn J. F., Rajbhandary R. A., Raskind M., Reisberg B., Ringman J. M., Roberson E. D., Rosenberg R. N., Sano M., Schneider L. S., Seeley W., Shelanski M. L., Slifer M. A., Smith C. D., Sonnen J. A., Spina S., Stern R. A., Tanzi R. E., Trojanowski J. Q., Troncoso J. C., Van Deerlin V. M., Vinters H. V., Vonsattel J. P., Weintraub S., Welsh-Bohmer K. A., Williamson J., Woltjer R. L., Cantwell L. B., Dombroski B. A., Beekly D., Lunetta K. L., Martin E. R., Kamboh M. I., Saykin A. J., Reiman E. M., Bennett D. A., Morris J. C., Montine T. J., Goate A. M., Blacker D., Tsuang D. W., Hakonarson H., Kukull W. A., Foroud T. M., Haines J. L., Mayeux R., Pericak-Vance M. A., Farrer L. A., Schellenberg G. D., Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics 2011 43 5 436 441 2-s2.0-79955464911 10.1038/ng.801
25. Jun G., Naj A. C., Beecham G. W., Wang L. S., Buros J., Gallins P. J., Buxbaum J. D., Ertekin-Taner N., Fallin M. D., Friedland R., Inzelberg R., Kramer P., Rogaeva E., St George-Hyslop P., Cantwell L. B., Dombroski B. A., Saykin A. J., Reiman E. M., Bennett D. A., Morris J. C., Lunetta K. L., Martin E. R., Montine T. J., Goate A. M., Blacker D., Tsuang D. W., Beekly D., Cupples L. A., Hakonarson H., Kukull W., Foroud T. M., Haines J., Mayeux R., Farrer L. A., Pericak-Vance M. A., Schellenberg G. D., Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Archives of Neurology 2010 67 12 1473 1484 2-s2.0-77957909886 10.1001/archneurol.2010.201
26. Carrasquillo M. M., Belbin O., Hunter T. A., Ma L., Bisceglio G. D., Zou F., Crook J. E., Pankratz V. S., Dickson D. W., Graff-Radford N. R., Petersen R. C., Morgan K., Younkin S. G., Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Archives of Neurology 2010 67 8 961 964 2-s2.0-77955463899 10.1001/archneurol.2010.147
27. Biffi A., Anderson C. D., Desikan R. S., Sabuncu M., Cortellini L., Schmansky N., Salat D., Rosand J., Genetic variation and neuroimaging measures in Alzheimer disease. Archives of Neurology 2010 67 6 677 685 2-s2.0-77953625064 10.1001/archneurol.2010.108
28. Mengel-From J., Christensen K., McGue M., Christiansen L., Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiology of Aging 2011 32 3, article 554 2-s2.0-79952899509 10.1016/j.neurobiolaging.2010.07.016
29. Daborg J., Andreasson U., Pekna M., Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. Journal of Neural Transmission 2012 119 7 789 797 10.1007/s00702-012-0797-8
30. McGeer P. L., Akiyama H., Itagaki S., McGeer E. G., Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neuroscience Letters 1989 107 13 341 346 2-s2.0-0024317005 10.1016/0304-3940(89)90843-4
31. Tooyama I., Kimura H., Akiyama H., McGeer P. L., Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease. Brain Research 1990 523 2 273 280 2-s2.0-0025335717 10.1016/0006-8993(90)91496-4
32. Perlmutter L. S., Scott S. A., Barrón E., Chui H. C., Erratum: MHC class II-positive microglia in human brain: association with Alzheimer lesions. Journal of Neuroscience Research 1992 35 3 346 2-s2.0-0027272103
33. Griffin W. S. T., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L. III, Araoz C., Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1989 86 19 7611 7615 2-s2.0-0001360461
34. Abraham C. R., Selkoe D. J., Potter H., Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988 52 4 487 501 2-s2.0-0023838532
35. Eikelenboom P., Stam F. C., Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathologica 1982 57 2-3 239 242 2-s2.0-0019993831
36. Rogers J., Cooper N. R., Webster S., Schultz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt B., Ward P., Lieberburg I., Complement activation by β -amyloid in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1992 89 21 10016 10020 2-s2.0-0026447529 10.1073/pnas.89.21.10016
37. Afagh A., Cummings B. J., Cribbs D. H., Cotman C. W., Tenner A. J., Localization and cell association of C1q in Alzheimer's disease brain. Experimental Neurology 1996 138 1 22 32 2-s2.0-0029932195 10.1006/exnr.1996.0043
38. Rozemuller A. J. M., Eikelenboom P., Theeuwes J. W., Jansen Steur E. N. H., de Vos R. A. I., Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathologica 2000 100 6 701 708 2-s2.0-0033770385 10.1007/s004010000225
39. Veerhuis R., Janssen I., de Groot C. J. A., van Muiswinkel F. L., Hack C. E., Eikelenboom P., Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Experimental Neurology 1999 160 1 289 299 2-s2.0-0032710620 10.1006/exnr.1999.7199
40. Shen Y., Lue L. F., Yang L. B., Roher A., Kuo Y. M., Strohmeyer R., Goux W. J., Lee V., Johnson G. V. W., Webster S. D., Cooper N. R., Bradt B., Rogers J., Complement activation by neurofibrillary tangles in Alzheimer's disease. Neuroscience Letters 2001 305 3 165 168 2-s2.0-0035877077 10.1016/S0304-3940(01) 01842-0
41. Strohmeyer R., Shen Y., Rogers J., Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Molecular Brain Research 2000 81 1-2 7 18 2-s2.0-0034734786 10.1016/S0169-328X(00)00149-2
42. Fonseca M. I., Zhou J., Botto M., Tenner A. J., Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. Journal of Neuroscience 2004 24 29 6457 6465 2-s2.0-3242766671 10.1523/JNEUROSCI.0901- 04.2004
43. Stevens B., Allen N. J., Vazquez L. E., Howell G. R., Christopherson K. S., Nouri N., Micheva K. D., Mehalow A. K., Huberman A. D., Stafford B., Sher A., Litke A. M., Lambris J. D., Smith S. J., John S. W. M., Barres B. A., The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 6 1164 1178 2-s2.0-36849076770 10.1016/j.cell.2007.10.036
44. Sárvári M., Vágó I., Wéber C. S., Nagy J., Gál P., Mák M., Kósa J. P., Závodszky P., Pázmány T., Inhibition of C1q- β -amyloid binding protects hippocampal cells against complement mediated toxicity. Journal of Neuroimmunology 2003 137 1-2 12 18 2-s2.0-17544395986 10.1016/S0165-5728(03) 00040-7
45. Singhrao S. K., Neal J. W., Rushmere N. K., Morgan B. P., Gasque P., Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. American Journal of Pathology 2000 157 3 905 918 2-s2.0-0034495294
46. Terai K., Walker D. G., McGeer E. G., McGeer P. L., Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Research 1997 769 2 385 390 2-s2.0-0030828544 10.1016/S0006-8993(97)00849-4
47. Smyth M. D., Cribbs D. H., Tenner A. J., Shankle W. R., Dick M., Kesslak J. P., Cotman C. W., Decreased levels of Clq in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiology of Aging 1994 15 5 609 614 2-s2.0-0028169558 10.1016/0197-4580(94)00055-7
48. Gay D., Esiri M., Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991 114 1 B 557 572 2-s2.0-0026013693
49. Alafuzoff I., Adolfsson R., Grundke-Iqbal I., Winblad B., Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathologica 1987 73 2 160 166 2-s2.0-0023237250
50. Claudio L., Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathologica 1996 91 1 6 14 2-s2.0-0029655250 10.1007/s004010050386
51. Fiala M., Liu Q. N., Sayre J., Pop V., Brahmandam V., Graves M. C., Vinters H. V., Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. European Journal of Clinical Investigation 2002 32 5 360 371 2-s2.0-0037000396 10.1046/j.1365-2362.2002. 00994.x
52. Minagar A., Alexander J. S., Blood-brain barrier disruption in multiple sclerosis. Multiple Sclerosis 2003 9 6 540 549 2-s2.0-0344961161 10.1191/1352458503ms965oa
53. Shen Y., Li R., McGeer E. G., McGeer P. L., Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Research 1997 769 2 391 395 2-s2.0-0030779518 10.1016/S0006-8993(97)00850-0
54. van Beek J., Bernaudin M., Petit E., Gasque P., Nouvelot A., MacKenzie E. T., Fontaine M., Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Experimental Neurology 2000 161 1 373 382 2-s2.0-0034052110 10.1006/exnr.1999.7273
55. Walker D. G., McGeer P. L., Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Molecular Brain Research 1992 14 1-2 109 116 2-s2.0-0026719683 10.1016/0169-328X(92)90017-6
56. Davoust N., Nataf S., Holers V. M., Barnum S. R., Expression of the murine complement regulatory protein Crry by glial cells and neurons. Glia 1999 27 2 162 170 2-s2.0-0033178257 10.1002/(SICI)1098-1136(199908)27:2162::AID- GLIA6>3.0.CO;2-K
57. Walker D. G., Kim S. U., McGeer P. L., Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. Journal of Neuroscience Research 1995 40 4 478 493 2-s2.0-0028923898 10.1002/jnr.490400407
58. Gasque P., Ischenko A., Legoedec J., Mauger C., Schouft M. T., Fontaine M., Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. The Journal of Biological Chemistry 1993 268 33 25068 25074 2-s2.0-0027363674
59. Walker D. G., Kim S. U., McGeer P. L., Expression of complement C4 and C9 genes by human astrocytes. Brain Research 1998 809 1 31 38 2-s2.0-0032569682 10.1016/S0006-8993(98)00811-7
60. Hosokawa M., Klegeris A., Maguire J., McGeer P. L., Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 2003 42 4 417 423 2-s2.0-0038458963 10.1002/glia.10234
61. Rutar M., Natoli R., Kozulin P., Valter K., Gatenby P., Provis J. M., Analysis of complement expression in light-induced retinal degeneration: synthesis and deposition of C3 by microglia/macrophages is associated with focal photoreceptor degeneration. Investigative Ophthalmology and Visual Science 2011 52 8 5347 5358 2-s2.0-80052920397 10.1167/iovs.10-7119
62. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., Kupchak P., Kireeva I., Ingratta L., Jackowski G., Mining biomarkers in human sera using proteomic tools. Proteomics 2004 4 1 244 256 2-s2.0-0942276226 10.1002/pmic.200300495
63. Akuffo E. L., Davis J. B., Fox S. M., Gloger I. S., Hosford D., Kinsey E. E., Jones N. A., Nock C. M., Roses A. D., Saunders A. M., Skehel J. M., Smith M. A., Cutler P., The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 2008 13 6 618 636 2-s2.0-53349145759 10.1080/13547500802445199
64. Veerhuis R., Janssen I., Hoozemans J. J. M., de Groot C. J. A., Hack C. E., Eikelenboom P., Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathologica 1998 96 3 287 296 2-s2.0-0031691401 10.1007/s004010050896
65. Yang L. B., Li R., Meri S., Rogers J., Shen Y., Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. Journal of Neuroscience 2000 20 20 7505 7509 2-s2.0-0034667686
66. Strohmeyer R., Ramirez M., Cole G. J., Mueller K., Rogers J., Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. Journal of Neuroimmunology 2002 131 1-2 135 146 2-s2.0-0036789954 10.1016/S0165-5728(02)00272-2
67. Raivich G., Like cops on the beat: the active role of resting microglia. Trends in Neurosciences 2005 28 11 571 573 2-s2.0-26944453586 10.1016/j.tins.2005.09.001
68. Vilhardt F., Microglia: phagocyte and glia cell. International Journal of Biochemistry and Cell Biology 2005 37 1 17 21 2-s2.0-4644308783 10.1016/j.biocel.2004.06.010
69. Helmut K., Hanisch U. K., Noda M., Verkhratsky A., Physiology of microglia. Physiological Reviews 2011 91 2 461 553 2-s2.0-79955605102 10.1152/physrev.00011.2010
70. Pocock J. M., Liddle A. C., Hooper C., Taylor D. L., Davenport C. M., Morgan S. C., Activated microglia in Alzheimer's disease and stroke. Ernst Schering Research Foundation workshop 2002 39 105 132 2-s2.0-0036368379
71. Fetler L., Amigorena S., Brain under surveillance: the microglia patrol. Science 2005 309 5733 392 393 2-s2.0-22244458574 10.1126/science.1114852
72. Fuhrmann M., Bittner T., Jung C. K. E., Burgold S., Page R. M., Mitteregger G., Haass C., Laferla F. M., Kretzschmar H., Herms J., Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nature Neuroscience 2010 13 4 411 413 2-s2.0-77950188666 10.1038/nn.2511
73. Edison P., Archer H. A., Gerhard A., Hinz R., Pavese N., Turkheimer F. E., Hammers A., Tai Y. F., Fox N., Kennedy A., Rossor M., Brooks D. J., Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease 2008 32 3 412 419 2-s2.0-56349144614 10.1016/j.nbd.2008.08.001
74. Rodríguez J. J., Witton J., Olabarria M., Noristani H. N., Verkhratsky A., Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer's disease. Cell Death and Disease 2010 1 1, article e1 2-s2.0-77949491472 10.1038/cddis.2009.2
75. Huang C., Wahlund L. O., Svensson L., Winblad B., Julin P., Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurology 2002 2 1, article 9 2-s2.0-0012691894
76. Ferretti M. T., Cuello A. C., Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Current Alzheimer Research 2011 8 2 164 174 2-s2.0-79954486783
77. Eikelenboom P., van Exel E., Veerhuis R., Rozemuller A. J. M., van Gool W. A., Hoozemans J. J. M., Innate immunity and the etiology of late-onset Alzheimer's disease. Neurodegenerative Diseases 2012 10 14 271 273 2-s2.0-84860218921 10.1159/000334287
78. Eikelenboom P., Veerhuis R., The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiology of Aging 1996 17 5 673 680 2-s2.0-0030250852 10.1016/0197-4580(96)00108-X
79. Block M. L., Hong J. S., Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Progress in Neurobiology 2005 76 2 77 98 2-s2.0-24144453087 10.1016/j.pneurobio.2005.06.004
80. Eikelenboom P., Veerhuis R., van Exel E., Hoozemans J. J. M., Rozemuller A. J. M., van Gool W. A., The early involvement of the innate immunity in the pathogenesis of lateonset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Current Alzheimer Research 2011 8 2 142 150 2-s2.0-79954509005
81. Barger S. W., Harmon A. D., Microglial activation by alzhelmer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997 388 6645 878 881 2-s2.0-0030610645 10.1038/42257
82. Davenport C. M., Sevastou I. G., Hooper C., Pocock J. M., Inhibiting p53 pathways in microglia attenuates microglial-evoked neurotoxicity following exposure to Alzheimer peptides. Journal of Neurochemistry 2010 112 2 552 563 2-s2.0-72849131778 10.1111/j.1471-4159.2009.06485.x
83. Morales I., Farías G., MacCioni R. B., Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. NeuroImmunoModulation 2010 17 3 202 204 2-s2.0-76949087724 10.1159/000258724
84. Craft J. M., Watterson D. M., Frautschy S. A., van Eldik L. J., Aminopyridazines inhibit β -amyloid-induced glial activation and neuronal damage in vivo. Neurobiology of Aging 2004 25 10 1283 1292 2-s2.0-4644316149 10.1016/j.neurobiolaging.2004.01.006
85. Lüth H. J., Ogunlade V., Kuhla B., Kientsch-Engel R., Stahl P., Webster J., Arendt T., Münch G., Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cerebral Cortex 2005 15 2 211 220 2-s2.0-12144278195 10.1093/cercor/bhh123
86. Berbaum K., Shanmugam K., Stuchbury G., Wiede F., Körner H., Münch G., Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine 2008 41 3 198 203 2-s2.0-39749155902 10.1016/j.cyto.2007.11.012
87. Gasic-Milenkovic J., Dukic-Stefanovic S., Deuther-Conrad W., Gärtner U., Münch G., β -Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon- γ and advanced glycation endproducts in a murine microglia cell line. European Journal of Neuroscience 2003 17 4 813 821 2-s2.0-0037293474 10.1046/j.1460-9568.2003.02506.x
88. Korotzer A. R., Watt J., Cribbs D., Tenner A. J., Burdick D., Glabe C., Cotman C. W., Cultured rat microglia express C1q and receptor for C1q: implications for amyloid effects on microglia. Experimental Neurology 1995 134 2 214 221 2-s2.0-0028805371 10.1006/exnr.1995.1051
89. Klickstein L. B., Barbashov S. F., Liu T., Jack R. M., Nicholson-Weller A., Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 1997 7 3 345 355 2-s2.0-0030873970 10.1016/S1074-7613(00)80356-8
90. Ling E. A., Kaur C., Yick T. Y., Wong W. C., Immunocytochemical localization of CR3 complement receptors with OX-42 in amoeboid microglia in postnatal rats. Anatomy and Embryology 1990 182 5 481 486 2-s2.0-0025077878
91. Martin U., Bock D., Arseniev L., Tornetta M. A., Ames R. S., Bautsch W., Köhl J., Ganser A., Klos A., The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. Journal of Experimental Medicine 1997 186 2 199 207 2-s2.0-0030739649 10.1084/jem.186.2.199
92. Arnaout M. A., Structure and function of the leukocyte adhesion molecule CD11/CD18. Blood 1990 75 5 1037 1050 2-s2.0-0025255615
93. Mevorach D., Mascarenhas J. O., Gershov D., Elkon K. B., Complement-dependent clearance of apoptotic cells by human macrophages. Journal of Experimental Medicine 1998 188 12 2313 2320 2-s2.0-0032416392 10.1084/jem.188.12.2313
94. Korb L. C., Ahearn J. M., C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. Journal of Immunology 1997 158 10 4525 4528 2-s2.0-0031569975
95. Bánki Z., Wilflingseder D., Ammann C. G., Pruenster M., Müllauer B., Holländer K., Meyer M., Sprinzl G. M., van Lunzen J., Stellbrink H. J., Dierich M. P., Stoiber H., Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. Journal of Immunology 2006 177 5 3469 3476 2-s2.0-33747748773
96. Hourcade D. E., Mitchell L., Kuttner-Kondo L. A., Atkinson J. P., Medof M. E., Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. The Journal of Biological Chemistry 2002 277 2 1107 1112 2-s2.0-0037059776 10.1074/jbc.M109322200
97. Maier M., Peng Y., Jiang L., Seabrook T. J., Carroll M. C., Lemere C. A., Complement C3 deficiency leads to accelerated amyloid β plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. Journal of Neuroscience 2008 28 25 6333 6341 2-s2.0-46749087854 10.1523/JNEUROSCI.0829-08.2008
98. Cheng M. H., Anderson M. S., Monogenic autoimmunity. Annual Review of Immunology 2012 30 393 427
99. Taylor P. R., Carugati A., Fadok V. A., Cook H. T., Andrews M., Carroll M. C., Savill J. S., Henson P. M., Botto M., Walport M. J., A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. Journal of Experimental Medicine 2000 192 3 359 366 2-s2.0-0034618113 10.1084/jem.192.3.359
100. Botto M., Dell'Agnola C., Bygrave A. E., Thompson E. M., Cook H. T., Petry F., Loos M., Pandolfi P. P., Walport M. J., Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genetics 1998 19 1 56 59 2-s2.0-0031778836 10.1038/ng0598-56
101. Wyss-Coray T., Yan F., Lin A. H. T., Lambris J. D., Alexander J. J., Quigg R. J., Masliah E., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proceedings of the National Academy of Sciences of the United States of America 2002 99 16 10837 10842 2-s2.0-0036679142 10.1073/pnas.162350199
102. Choucair-Jaafar N., Laporte V., Levy R., Poindron P., Lombard Y., Gies J. P., Complement receptor 3 (CD11b/CD18) is implicated in the elimination of β -amyloid peptides. Fundamental and Clinical Pharmacology 2011 25 1 115 122 2-s2.0-78650940497 10.1111/j.1472-8206.2010.00811.x
103. Ilschner S., Nolte C., Kettenmann H., Complement factor C5a and epidermal growth factor trigger the activation of outward potassium currents in cultured murine microglia. Neuroscience 1996 73 4 1109 1120 2-s2.0-0029930669 10.1016/0306-4522(96)00107-8
104. Nolte C., Möller T., Walter T., Kettenmann H., Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience 1996 73 4 1091 1107 2-s2.0-0342592138 10.1016/0306-4522(96)00106-6
105. Hoffmann A., Kann O., Ohlemeyer C., Hanisch U. K., Kettenmann H., Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. Journal of Neuroscience 2003 23 11 4410 4419 2-s2.0-0038795206
106. Nunes P., Demaurex N., The role of calcium signalling in phagocytosis. Journal of Leukocyte Biology 2010 88 1 57 68 10.1189/jlb.0110028
107. Ager R. R., Fonseca M. I., Chu S. H., Sanderson S. D., Taylor S. M., Woodruff T. M., Tenner A. J., Microglial C5aR (CD88) expression correlates with amyloid- β deposition in murine models of Alzheimer's disease. Journal of Neurochemistry 2010 113 2 389 401 2-s2.0-77949725218 10.1111/j.1471-4159.2010. 06595.x
108. Fonseca M. I., Ager R. R., Chu S. H., Yazan O., Sanderson S. D., LaFerla F. M., Taylor S. M., Woodruff T. M., Tenner A. J., Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. Journal of Immunology 2009 183 2 1375 1383 2-s2.0-69249152289 10.4049/jimmunol.0901005
109. Persson M., Pekna M., Hansson E., Rönnbäck L., The complement-derived anaphylatoxin C5a increases microglial GLT-1 expression and glutamate uptake in a TNF- α -independent manner. European Journal of Neuroscience 2009 29 2 267 274 2-s2.0-58449100948 10.1111/j.1460-9568.2008. 06575.x
110. Ramaglia V., Hughes T. R., Donev R. M., Ruseva M. M., Wu X., Huitinga I., Baas F., Neal J. W., Morgan B. P., C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2012 109 3 965 970 2-s2.0-84856390379 10.1073/pnas.1111924109
111. Mastellos D., Papadimitriou J. C., Franchini S., Tsonis P. A., Lambris J. D., A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. Journal of Immunology 2001 166 4 2479 2486 2-s2.0-0035865055
112. Drouin S. M., Sinha M., Sfyroera G., Lambris J. D., Wetsel R. A., A protective role for the fifth complement component (C5) in allergic airway disease. American Journal of Respiratory and Critical Care Medicine 2006 173 8 852 857 2-s2.0-33646360582 10.1164/rccm.200503-334OC
113. Wang Z., Zhang S., Tong Z., Li L., Wang G., Maternal transfer and protective role of the alternative complement components in zebrafish Danio rerio. PLoS ONE 2009 4 2 2-s2.0-60949085892 10.1371/journal.pone.0004498 e4498
114. Mukherjee P., Thomas S., Pasinetti G. M., Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. Journal of Neuroinflammation 2008 5, article 5 2-s2.0-39649121460 10.1186/1742-2094-5-5
115. O'Barr S. A., Caguioa J., Gruol D., Perkins G., Ember J. A., Hugli T., Cooper N. R., Neuronal expression of a functional receptor for the C5a complement activation fragment. Journal of Immunology 2001 166 6 4154 4162 2-s2.0-0035869453
116. Pasinetti G. M., Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiology of Aging 1996 17 5 707 716 2-s2.0-0030250826 10.1016/0197-4580(96)00113-3
117. Topaloglu R., Bakkaloglu A., Slingsby J. H., Mihatsch M. J., Pascual M., Norsworthy P., Morley B. J., Saatci U., Schifferli J. A., Walport M. J., Molecular basis of hereditary C1q deficiency associated with SLE and IgA nephropathy in a Turkish family. Kidney International 1996 50 2 635 642 2-s2.0-9444254614
118. Marquart H. V., Schejbel L., Sjoholm A., Martensson U., Nielsen S., Koch A., Svejgaard A., Garred P., C1q deficiency in an Inuit family: identification of a new class of C1q disease-causing mutations. Clinical Immunology 2007 124 1 33 40 2-s2.0-34250779543 10.1016/j.clim.2007.03.547
119. Johnson S. A., Lampert-Etchells M., Pasinetti G. M., Rozovsky I., Finch C. E., Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiology of Aging 1992 13 6 641 648 2-s2.0-0026622098 10.1016/0197-4580(92)90086-D
120. Singhrao S. K., Neal J. W., Morgan B. P., Gasque P., Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Experimental Neurology 1999 159 2 362 376 2-s2.0-0032873347 10.1006/exnr.1999.7170
121. Huang J., Kim L. J., Mealey R., Marsh H. C. Jr., Zhang Y., Tenner A. J., Connolly E. S. Jr., Pinsky D. J., Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein. Science 1999 285 5427 595 599 2-s2.0-0033597941 10.1126/science.285.5427.595
122. Lee C. K., Weindruch R., Prolla T. A., Gene-expression profile of the ageing brain in mice. Nature Genetics 2000 25 3 294 297 2-s2.0-0000847978 10.1038/77046
123. Tenner A. J., Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiology of Aging 2001 22 6 849 861 2-s2.0-0035695984 10.1016/S0197-4580(01)00301-3
124. Pisalyaput K., Tenner A. J., Complement component C1q inhibits β -amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. Journal of Neurochemistry 2008 104 3 696 707 2-s2.0-38049107388 10.1111/j.1471-4159.2007.05012.x
125. Fu H., Liu B., Frost J. L., Hong S., Jin M., Ostaszewski B., Shankar G. M., Costantino I. M., Carroll M. C., Mayadas T. N., Lemere C. A., Complement compoment C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar A β by microglia. Glia 2012 60 6 993 1003